The John F. Kennedy Library and Museum Foundation shared two photos from the ceremony, congratulating President Kennedy’s ...

Only two men can tell us if Elon Musk and Trump are truly, as of December 2025, “friends.” But the formal definition I used ...

Ultragenyx and Mereo BioPharma hit 52-week low after disappointing results from Phase 3 studies for Osteogenesis Imperfecta ...

The new analysis study showed the delay may stem from genetic mutations that are present when a child is born – but activate ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most active US stocks to buy according to analysts. On December 8, ...

An in-depth look at Tianqiao Chen's argument that AI-native companies will dismantle traditional corporate structures, ...

Ultragenyx Pharma announces phase 3 Orbit & Cosmic results for setrusumab in osteogenesis imperfecta: Novato, California Wednesday, December 31, 2025, 18:00 Hrs [IST] Ultragenyx P ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the AI stocks under $20 to buy now. On December 8, Recursion ...

Orcas have spent the past few years rewriting their public image from charismatic performers to unpredictable disruptors, ...

It’s hard to keep up with all the discoveries made around the world every year in science, but harder still to sort the hype ...

Ultragenyx is developing setrusumab in pediatric and young adult patients across OI sub-types I, III and IV with two late-stage studies: the pivotal Phase 2/3 Orbit study and Phase 3 Cosmic study.